In 2013, we developed a proprietary enzymatic biosynthesis production system in order to improve the taste of stevia, a natural compound used as a high-potency sweetener. This platform harnesses a naturally-occurring biological process known as glycosylation, which involves using enzymes to attach glucose (sugars) to small-molecule compounds. Over the last 10 years or so, it has become well appreciated within the pharmaceutical industry that glycosylation can act to generate new natural product libraries with improved drug properties. This platform technology enables us to readily modify existing drug compounds, especially natural products, in order to give them attractive new drug properties.
Using our proprietary glycosylation platform, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel drug candidates that represent a new class of cannabinoid pharmaceuticals. It is well established that cannabis can provide relief of pain and inflammation in certain disease indications, and our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as targeted drug delivery that avoids or reduces psychoactivity. Targeted delivery through glycosylation may enable selective delivery of compounds to the brain or gut, markedly improving the side effect profile or bioavailability of existing drugs.
Vitality has filed intellectual property applications and is seeking worldwide patent protection through 2035 with strong composition of matter claims for prodrugs of THC, CBD, and CBDV, as well as for its proprietary prodrug biosynthesis platform utilizing enzymatic glycosylation.